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Summary.-A mouse monoclonal antibody (LICR-LON/HT13) has been developed
to a cell-surface antigen carried on a human germ-cell tumour xenograft (HX39).
After radioiodination, the antibody localized in vivo preferentially in xenografted
tumours as opposed to normal mouse tissue, whereas tumour uptake did not occur
with normal mouse IgG or nonspecific monoclonal IgG. This selective localization
could be abolished by simultaneous injection of an excess of the unlabelled LICR-
LON/HT13.
The kinetics of and factors influencing localization have been examined. Tumour
weight was important in that the smaller the tumour the better the localization.
LICR-LON/HT13 was found to localize also in other xenografted germ-cell tumours,
but not in non-germ-cell tumour xenografts.
Thus monoclonal antibodies are capable of selective in vivo localization of human
tumours in an animal model, and their clinical value should now be assessed.
THE CONCEPT of radiolabelled anti-
tumour antibodies to localize animal
tumours in vivo was introduced by Press-
man et al. (1957) and extended to human
tumours by the use of affinity-purified
antibodies to CEA, which were shown to
localize preferentially in CEA-containing
human colon (Mach et al., 1974; Primus
et al., 1973) and human breast tumours
(Moshakis et al., 1981a) xenografted into
animals. Subsequently, radiolabelled anti-
bodies to CEA (Goldenberg et al., 1978;
Mach et al., 1980a; Dykes et al., 1980),
human chorionic gonadotrophin (Begent
et al., 1980; Bagshawe et al., 1980) and
alphafoetoprotein (Goldenberg et al., 1980)
were successfully applied in clinical prac-
tice by the use of y-camera external
photoscanning. However, a computerized
subtraction technique has been used by
all workers in order to eliminate blood-
background radioactivity and to permit
detection of the target tumour. This may
be liable to interpretive error and has left
some workers unconvinced (Houston et
al., 1980), while others have expressed
doubt about the clinical applicability of
conventionally raised antibodies to estab-
lished tumour markers (Mach et al.,
1980a, b).
Monoclonal antibodies can be raised to
antigens of choice, and may offer a specific
and selective approach. Their recent
development (Kohler & Milstein, 1975)
together with the production ofthe human
tumour xenograft system in immune-
suppressed mice has enabled us to evaluate
the potential of these new reagents for
tumour localization before clinical studies.
AIATERIALS AND METHODS
Antibody and iodine labelling.-The cell line
HX39/7, established from xenografted un-
differentiated human malignant teratoma
(MTU) (Raghavan et al., 1980) was used to
immunize mice. Three weeks after the first
injection of 107 cells, a second i.p. injection
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spleen was remnoved from the mice. Spleen
cells were fused with the mnyeloma NSI (gift
of Dr C. Milstein) using a modification of the
method of Galfre et al. (1977). The cells, were
plated in soft agar using mouse thymocytes
as feeder cells (Edwards et al., 1980) and viable
antib)ody-producing hybrid clones Mwere picked
from the agar 11-12 days after fusion.
Antibodies l)inding to the teratoma cells
(HX39/7) were detected by using 1251-F(ab)2
as second antibody (rabbit anti-mouse IgG)
in the assay system of Williams et al. (1977).
The hybrid clone producing a suitable anti-
body -was chosen for subsequent use and wNas
grown in ascitic form in mice. The ascitic
fluid was collected from this and the antibody
was purified by precipitation uwith 5000
(NH4)2SO4 and Sephadex G-200 chromatog-
raphy. Immunochemical and biochemical
studies showed the antibody to be of the IgG
2a class.
For localization studies the antibody wias
iodiniated with 1251, using chloramine-T
(Greenwiood et al., 1963) as follows: 100 ,ug of
antibody (100 t1 in PBS) was reacted with
Na 1251 (1 mCi Amersham. Code IMS 30)
and chloramine-T (10 Htg/ml in D20). After
1 min, the reaction was stopped by the addi-
tion of 100 jig of sodium metabisulphite.
Free iodine was removed by gel-filtration
chromatograplhy, using a G25 Sephadex
column eluting writh 0-5o BSA in PBSA
(lml fractions were collected). A specific
activity of 5 ,uCi/ug was achieved. As con-
trols for nonspecific accumnulation of proteins
in tumours and tissues, normal mouse immu-
noglobulins (Miles) and a mouse monoclonal
IgG (FIB-75), which bound only wx-eakly to
HX39/7 teratoma cells in vitro (Mcllhinney,
1980), were iodinated Xwith 1311 to equivalent
specific activities.
The iodinated reagents were passed through
a Sephacryl S-300 (0 9 cm x 60 cm) column in
order to establish the presence or absence of
aggregates or degradation products of the
irnmunoglobulin after the I-labelling. The
antibodies -were eluted with 0IM phosphate
buffer (pH 7-5) at a rate of 5 ml/h. 0 5ml
fractions were collected and the radioactivitv
of eachi fraction (1251 and 1311) was measured
wN-ith an LKB-1280 ultra-gamma counter. In
addition, after injection of the radiolabelled
antibodies and exsanguination of the animals
at, predetermined intervals, plasma samples
wi-ere passed through the column. The plasma
profiles of animals bearing small or large
tumours or from tumour-free animals, were
investigated.
Animal model. Four-week-old CBA/lac
mice, weighing on average 23 g, were immune-
suppressed by thymectomy and total-body
irradiation preceded by i.p. administration of
arabinoside C (Steel et al., 1978). Two-mm
cubes of tumour were implanted s.c. in each
flank and allowed to grow, for 12-28 days
before an experiment was started. We were
thus able to test tumours of various weights
ranging from 6 mg to 1102 mg. The viability
of small tumours was confirmed at histo-
logical examination. The presence of mitoses
was taken as evidence that tumours were
actively growing. In addition to the HX39
teratoma, against which the antibody was
raised, me tested 4 other germ-cell tumour
xenografts and 3 non-germ-cell tumours. All
the xenografts used in these studies were of
human origin, and have been shown to main-
tain the same histology as the primary
tumour, and human karyotype, throughout
passage. The germ-cell tumour xenografts,
details of which have been published pre-
viously (Raghavan et al., 1980), Mwere: (a)
HX112/3, yolk-sac carcinoma; (b) HX57/17,
yolk-sac carcinoma; (c) HX53/14, seminoma
with yolk-sac carcinoma elements, and (d)
HX111/3, malignant teratoma undifferen-
tiated (MTU). The other tumours were: (a)
HX99/12, breast adenocarcinoma (Bailey
et al., 1980); (b) HX65/3, bronchial adeno-
carcinoma (Shorthouse et al., 1980), and (c)
HN.BR/3, squamous-cell carcinoma (Easty
(t al., in preparation).
Radiolocalization. Simultaneous i.v. in-
jection of 10-15 .tCi each of 1251-labelled
monoclonal antibody and 1311-labelled mouse
IgG was given to tumour-bearing and
tumour-free animals. Owing to variability in
the labelling efficiencies, the amounts of
inonoclonal antibody and normal IgG were
not always equal. At intervals of 4-96 h
after injection, the animals were exsanguina-
ted by cardiac puncture and tumours and
organs (salivary gland, thyroid gland, heart,
lungs, liver, spleen, stomach, kidney, intestine
and thigh muscle) w%ere removed. After each
tissue had been weighed, radioactivity was
measured with a LKB-1280 ultra-gamma
counter.
The results are expressed as: (a) localization
index (LI), i.e. the ratio of specific (1251) to
nonspecific (1311) activity in tumours and
organs divided by the same ratio in the bloodHUMAN TUAIOURS LOCATED BY AIONOCLONAL ANTIBODIES
and (b) absolute radioactivity, i.e., ct/min/mg
wet weight. The LI provides a standardized
method of comparing results between experi-
ments, and is similar to the localization ratio
used by Primus et al. (1973) and the specificity
index used by Mach et al. (1974), except that
the former authors made a comparison with
the ratio in the injected solution, and the
latter with the liver.
RESULTS
Twenty hybridoma clonies making anti-
body against the immunizing teratoma cell
line were identified by the binding assay,
as described above. One clone, LICR-LON/
HT13, grew vigorously, and consistently
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FIG. 1.Ch1romatography profiles of 125I-
labelled LICR-LON/HT13. (a) Sephadex
G25; (b) Sephacryl S-300.
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FIG. 2. In vivo localization of LICR-LON/
HTI 3 in HX39 lhuman germ-cell tumour
xenografts. (a) Single experiment: values
are means + s.e. of 4-8 tumours (total 24);
mean tumour weight: 17 mg. (b) Six
separate experiments. 4-8 tumours in each
sample (total 90); mean tumotir weight
12-2 mg (range 7-17 mg).
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TABLE I. Tumour (T)/organ ratio at 24
and 96 h after injection of labelled mono-
clonal antibody
Tumour/organ
ratio
(ct/min/mg)
T./blood
T./liver
T./thyroidl gland
T./salivary glan(1
T./stomacl
T./spleen
T./lung
T./kidney
T./intestine
T./heart
T./muscle
24 h
2-1 + 0-8
5-6+0-6
5-8 + 1-2
6-3+0-9
7-8 + 1*6
9-9 + 1-3
11-9+ 2-6
15-0 + 1*9
14-5 + 1*8
14-6 + 2 0
15-0+ 1-6
* Means + s.e. of 5 experiments
experiments (96 h) as slhown in Fig.
96 hi
9-1 +2 0
15-3 + 1-9
16-1 + 1*8
19-6 + 2-7
19-9+44-5
28-1 + 3-1
36-3 +5-6
43-4 + 6-6
44-9+5-1
55-7+7-1
58-3+6-8
(24 It) an(I 4
2b.
yielded high levels of binding (> 104
ct/min/105 cells) in the binding assay.
It was therefore chosen for the production
ofantibody used for the in vivo localization
of the germ-cell xenograft HX39 (Passage
Numbers 8-17). Chromatography of the
radiolabelled antibody with Sephadex
G-25 column showed that satisfactory
separation ofthe antibody from free iodine
was achieved (Fig. la). Subsequent pas-
sage of the labelled antibody throughthe
Sephacryl S-300 column showed that all
the radioactivity eluted in the expected
IgG position, and that the reagent was
free from aggregates and degradation pro-
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ducts (Fig. lb). The above applied to the
iodination of all 3 reagents (the specific
monoclonal antibody LICR-LON/HT13,
the normal mouse IgG and the nonspecific
monoclonal IgG FIB-75).
Analysis of LI shows that there is an
increasingly selective uptake of the mono-
clonal antibody by the tumour with time,
whereas the index in the liver is much
lower andremains constantthroughout the
experiment (Fig. 2a). Among normal
tissues, the liver was found to take up the
highest amount of monoclonal antibody
(Table I). It was therefore used as our
standard organ for comparison with the
tumour. All other organs contained lesser
amounts of antibody, with muscle and
intestine having the lowest concentration.
In the tumour the monoclonal antibody/
IgG ratio increased with time, indicating a
higher uptake of the specific antibody by
the tumour than of normal IgG, whereas
the same ratio in the blood remained rela-
tively constant (Fig. 3a). Therefore, itwas
the former ratio (tumour) that contributed
most to the increase in LI, rather than the
latter (blood), which did not change
appreciably throughout the experiment.
The collected results of 6 experiments,
involving a total of 90 tumours, is shown
in Fig. 2b.
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FIG. 4.-Distribution of normal mouse JgG in
animals carrying HX39 human germ-cell
tumour xenografts. 0 Blood; A liver;
* salivary gland; 0 tumour; U muscle.
The values in the other organs lie between
those of liver and salivary gland (highest
uptake) and muscle (least uptake). Values
are means of 6 samples; mean tumour
weighit 11I mg.
75. an JgG 2a, was iodinated with 1311
and used as the control, replacing the
normal mouse JgG. This antibody showed
very weak binding to HX39/7 cells in vitro
(Mcllhinney, 1980) and its behaviour in
the animal was the same as that ofnormal
mouse JgG (Fig. 4). No difference in the
degree of localization was obtained when
FIB-75 was used as the nonspecific JgG
rather than the normal mouse IgG. There-
fore the localization of LICR-LON/HTi 3
in the tumour was not an idiosyncrasy of
the monoclonal antibody.
The clearance ofthe antibody, expressed
as absolute concentration of activity
(ct/mmn/mg) from the tumour, normal
tissues and blood was studied (Fig. 5). The
concentration in the tumour started to
exceed that of normal tissues and blood
at 4-24 h after injection. Although there-
after the amount of antibody in the tu-
mour decreased, it did so at a slower rate
than blood and normal tissues; thus the
tumour/non-tumour ratio (Table I) and
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FiG. 5. Clearance of 12251-labelled LICR-
LON/HT13 from tumour (HX39), bloodand
liver. Values (from a single experiment) are
means+ s.e. of 6-8 samples; mean tumour
weight 16 mg.
the tumour/blood ratio (Fig. 3b and c)
increased with time. In contrast, the nor-
mal IgG behaved indifferently to the
presence of tumour; its clearance from
the tumour was similar to that of all the
other tissues studied and its concentration
was always lower than in blood (Fig. 4).
Since the ratio of 1251-labelled LICR-
LON/HT13 to 1311-labelled normal mouse
IgG was the same in normal organs of the
experimental animals and did not change
appreciably with time, the distributions
of the two antibodies in normal tissues
appear similar. In our system, the specific
antibody tumour/blood ratio was between
0-4 at 4 h and 10 at 96 h after injection,
demonstrating a 2-fold (4 h) to a 14-fold
(96 h) increase over the same ratio with
normal IgG (Fig. 3a). Similarly, the
specific antibody tumour/blood ratio
showed a 3-fold (4 h) to a 20-fold (96 h)
increase over the liver/blood ratio (Fig.
3c).
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Fic. 6. Chromatography profile (Sephiacryl S-300) of 125J-labelled LICR-LON/HT13 in plasma of
animals carrying HX39 human germ-cell tumour xenografts at 4, 24 and( :38 li.
The localization described above could
be inhibited by simultaneous i.v. injection
of non-radiolabelled LICR-LON/HT13
(100 aug/animal), indicating that the cold
antibody was capable of blocking the
tumour antigenic sites, thus inhibiting
uptake of further (radiolabelled) antibody
by the tumour. In parallel experiments,
such inhibition was not found when cold
FIB-75 IgG was used.
If the localization observed is due to
antibody-antigen reaction, it might be
expected to occur rapidly after injection,
and therefore selective homing of the
antibody to the tumour should be detected
by 4 h, when the first dissection of the
animals took place. Indeed, it was found
with the tumour/blood and tumour/non-
tumour ratios with the monoclonal IgG
were higher than the same ratios with the
normal IgG 4 h after injection (Fig. 3b).
Similarly, the specific-antibody tumour/
blood ratio is superior to liver/blood ratio
(Fig. 3c) as early as 4 h after injection.
The same pattern is seen when the
monoclonal antibody/normal IgG ratio in
the tumour is compared to that in the
blood (Fig. 3a).
Plasma samples ofinjected animals were
passed through Sephacryl S-300 columns.
The IgG eluted consistently at the expec-
ted fractions, with no peaks of radio-
activity before or after the IgG peak,
indicating that large molecules had not
been formed and no degradation of anti-
body had taken place (Fig. 6). It was
thought that shedding of antigen to the
circulation from large tumours (which
showed no uptake) may inhibit localiza-
tion, as it would react with the injected
antibody. However, the plasma profiles
of large tumours (0 8-1 1 g) was the same
as that ofsmall tumours (8-86 mg).
Tumour weight was found to be impor-
tant, in that the smaller the tumour the
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FIG. 7. The localizationi index of LICR-
LON/HTl3 in 3 different experiments (0,
* an(l A) witlh tumours (HX39) ofvarying
weights, dissected ancl countedi 48 lI after
injection.
IHUMfAN TUAIOURS LOCATED BY MONOCLONAL ANTIBODIES
TABLE II. Localization of ter
non-teratoma xenografts vi ith
ton/a antibody LICR-LON/H
Tumour
HX39
HX112
HXIlI
HX53
HX57
HX99
HX65
1HN.BR
Pathiology
MITUt with yolk-sac
elements
Yolk-sac carcinoma
AITU
Seminoma with yolk-sac
elements
Yolk-sac carcinoma
Breast adenocarcinoma
Bronchial adenocarcinioma
Squamous-cell carcinoma
* Aeanl of 4-8 tumoturs at eachi ti
weight, 15 22 mg.
ttumour or tissi
Localization inex - 125Id-
Bloo( 1311
t MITU Mlalignlant teratoma undiffe
better the localization. No
selective uptake of the antibc
tumour was found in tumour:
above 200-250 mg (Fig. 7).
animals carrying 2 tumours c
weights, this difference was
(indicating that this phenorr
tumour-dependent rather tha
dependent).
The specificity of the loca
LICR-LON/HT13 for the gern
toma HX39/7 was tested in oth
by using 4 additional germ-cell
germ-cell xenografts. In vivo 1
occurred in all the teratoma lii
in the non-teratoma tumours
The degree of localization varie
the teratomas, but in none wae
as for the HX39/7 tumour.
DISCUSSION
This work demonstrates tha
clonal antibody raised against
component of a human tumoui
is capable of selective localizati
a tumour after its in vivo adm
This was demonstrated as follo
uptake ofthe antibody by the t
higher than in blood and norn
atoma and (b) localization did not occur with normal
> anti-tera- mouse IgG or an indifferent monoclonal
IT] 3* antibody, (c) blocking of the antigen with
LIt excess antibody inhibited selective uptake
and (d) preferential localization in the
481i 996 h tumour was demonstrated not only with
7*0 10-9 regard to normal mouse tissues and with
65 7.7 normal IgG but also with regard to other
3-8 5-6 tumours. The above findings support the
4-0 3-6 hypothesis that the in vivo localization is
248 2-9 due to the interaction of the injected anti-
1.1 1-1 body with the cell-surface antigen. Further
1t2 Li. evidence for this arises from preliminary
1-6 1-4
work, where we have shown by auto- me. Tumour radiography that, afteri.v. administration,
1251 the monoclonal antibody is located in
Ule i31i viable parts of the tumour and often seen
to be closely applied to the periphery of
individual HX39 teratoma cells (Moshakis
et al., 1981b).
The absence of immune complexes
significant (large molecules eluting before the IgG
dy by the peak) in the plasma of the animals after
s weighing antibody injection suggests that the target
In single cell-surface antigen does not reach the
)f different circulation. This, however, should not be
also noted taken as aiding localization, since similar
ienon was work with antibodies to soluble tumour
Ln animal- markers in patients and animals has
shown that the presence of circulating
,lization of antigen does not, surprisingly, have any
n-cell tera- relevance to the degree of localization
.er tumours (Goldenberg et al., 1980; Moshakis et al.,
and 3 non- 1981a).
Localization Comparison of the concentration of the
nes butnot two radioisotopes in tumour, tissues and
(Table II). blood have made it possible to attribute
d amongst the selective uptake ofthe antibody by the
s it as high tumour to the binding properties of the
antibody itself. Non-immunological fac-
tors that would affect the entry and hand-
ling of IgG by the tumour, such as vascu-
larity, necrosis, lymphatic drainage and
it a mono- extracellular space, would apply equally
t a surface to both specific and normal IgG. It appears
r xenograft that the technique of double-isotope
ion in such labelling (Pressman et al., 1957) still
inistration. remains of great assistance in this field,
iws: (a) the especiallyintheexperimental animalwhich
umour was can be killed and tissue radioactivity
nal tissues, measured. This becomes more important
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when new reagents, such as monoclonal
antibodies, are exploited for this purpose.
Demonstration of localization in the
animal model ofhuman tumour xenografts
lessens, but does not abolish, the need for
such studies when this approach is used
in patients, where tissue dissection is not
often possible.
Correlation between in vivo localization
and in vitro binding to cells was not pos-
sible when other teratomas were used,
because none of the other 4 xenografts
have been established in tissue culture.
Nevertheless, the behaviour of the anti-
body and the normal IgG, together with
the localization kinetics, were similar
to the pattern seen when LICR-LON/
HT13 used to localize the HX39 tumour.
The specific uptake of the monoclonal
antibody was highest in the HX39
tumour (against which the antibody was
raised). This suggests that, although the
antigen is present in all the germ-cell
tumours examined, its "expression" was
less in the other tumours than that which
acted as an immunogen. Since the tumours
examined contain varying amounts of
yolk-sac carcinoma, seminoma and un-
differentiated malignant teratoma, further
studies are required, to correlate germ-cell
tumour histology and site of antibody
uptake at a cellular level. Such a study
might reveal the reason for the varying
degrees of localization of antibody among
germ-cell tumours.
This study of tumour localization and
the parameters which affect it, using a
monoclonal antibody against a surface
antigen on a human teratoma cell line,
shows that such antibodies do localize
in vivo and that they are, therefore, good
candidates for clinical use, such as immu-
noscanning and tumour-drug targeting.
In this respect, the property of the anti-
body to localize in small tumours could
prove very useful in detecting micro-
metastases in patients, especially when
the newer tomographic scanning tech-
niques are fully developed. In the past,
computerized background subtraction of
the blood pool has been used in every case
when conventionally raised antisera have
been used to detect tumours in patients.
However, the tumour/blood ratios ob-
tained with monoclonal antibodies may
make this technique unnecessary; Ballou
et al. (1979) using a monoclonal antibody,
have shown that murine tumours can be
detected without background subtrac-
tion, if the scan is performed more than
48 h after antibody injection. It must be
emphasized, however, that although the
tumour/blood ratio increases with time
the absolute amount of activity in the
tumour decreases. The optimal time,
therefore, for scanning is a balance between
these two factors. It is interesting that our
study, and those of others using mono-
clonal antibodies for localization (Ballou
et al., 1979; Houston et al., 1980), demon-
strate better tumour/blood and tumour/
non-tumour ratios than those obtained
with conventional antibodies to soluble
tumour markers. However, it should not
be forgotten that the antibodies used are
of murine origin and injected into mice.
Their value can only be assessed fully
when these reagents are injected into
patients.
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